COULD NUCLEOLIN AND NUCLEOPHOSMIN LEVELS BE A PROGNOSTIC INDICATOR IN NON SMALL CELL LUNG CANCER?
Abstract
Objective: Lung cancer is the leading cause of mortality from cancer across the world. In this study, the use of serum nucleolin (NCL) and nucleophosmin (NPM1) levels as a marker in the diagnosis, prognosis and treatment response evaluation in lung cancer was investigated.
Materials and Method: NCL and NPM1 levels of serum samples taken before chemotherapy and after 3-4 courses of chemotherapy from the control group and the patients diagnosed with lung cancer were studied by ELISA method.
Findings: Serum NCL, NPM1 levels of the patients were higher than the controls (p=0.085 for NCL, p=0.000 for NPM1). NCL and NPM1 levels by histopathologic type were significantly higher in adenocarcinoma than squamous cell carcinoma (p<0.05 for each). In view of the treatment responses of chemotherapeutic agents, there was a statistically insignificant difference between the values before and after chemotherapy (p>0.05 for each).
Conclusion: High serum NCL and NPM1 levels were found to correlate with poor prognosis, poor treatment response and low survival. It can be concluded that serum NCL and NPM1 levels in lung cancer can be used as a diagnostic and prognostic marker for the disease.
References
1.Ferlay J, Colombet M, Soerjomataram I et al. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.
- Bray F, Ferlay J, Soerjomataram I Siegel RL, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313. PMID: 30207593.
- Hirsch FR, Scagliotti GV, Mulshine JL et al. Lung cancer: current therapies and new targeted treatments. The Lancet 2017;389:299–311.
4.Lee JH, Lee YS, Jeong SA et al. Catalytically active telomerase holoenzyme is assembled in the dense fibrillar component of the nucleolus during S phase. Histochem Cell Biol. 2014;141(2):137-152. doi:10.1007/s00418-013- 1166-x. .
5.Li N, Yuan K, Yan F, et al. PinX1 is recruited to the mitotic chromosome periphery by Nucleolin and facilitates chromosome congression. Biochem Biophys Res Commun. 2009;384(1):76-81. doi:10.1016/j.bbrc.2009.04.077.
6.Grisendi S, Mecucci C, Falini B et al. Nucleophosmin and cancer. Nat Rev Cancer. 2006 Jul;6(7):493-505. doi: 10.1038/nrc1885. PMID: 16794633.
- Chen S, He H, Wang Y, et al. Poor prognosis of nucleophosmin overexpression in solid tumors: A meta-analysis. Bmc Cancer. 2018;18:838. doi: 10.1186/s12885-018-4718-6.
- Hsu TI, Lin SC, Lu PS et al. MMP7-mediated cleavage of nucleolin at Asp255 induces MMP9 expression to promote tumor malignancy [published correction appears in Oncogene. 2017 Feb 9;36(6):875-876]. Oncogene. 2015;34(7):826-837. doi:10.1038/onc.2014.22. .
- Zhao H, Huang Y,et al. Prognostic significance of the combined score of endothelial expression of nucleolin and CD31 in surgically resected non-small cell lung cancer. PLoS One. 2013;8(1):e54674. doi: 10.1371/journal.pone.0054674. Epub 2013 Jan 31.
- Huang F, Wu Y, Tan H et al. Phosphorylation of nucleolin is indispensable to its involvement in the proliferation and migration of non-small cell lung cancer cells. Oncol Rep. 2019 Jan;41(1):590-598. doi: 10.3892/or.2018.6787.
11.Xu JY, Lu S, Xu XY et al. Prognostic significance of nuclear or cytoplasmic nucleolin expression in human non-small cell lung cancer and its relationship with DNA-PKcs. Tumour Biol. 2016 Aug;37(8):10349-56. doi: 10.1007/s13277-016-4920-6. Epub 2016 Feb 4. PMID: 26846099.
- Zhou Y, Shen J, Xia L et al. Estrogen mediated expression of nucleophosmin 1 in human endometrial carcinoma clinical stages through estrogen receptor-α signaling. Cancer Cell Int. 2014 Dec 20;14(1):540. doi: 10.1186/s12935-014-0145-1. PMID: 25663821; PMCID: PMC4319226.
- Sekhar KR, Benamar M, Venkateswaran A et al. Targeting nucleophosmin 1 represents a rational strategy for radiation sensitization. Int J Radiat Oncol Biol Phys. 2014 Aug 1;89(5):1106-1114. doi: 10.1016/j.ijrobp.2014.04.012. Epub 2014 Jul 8. PMID: 25035215; PMCID: PMC4105849.
- He J, Xiang Z, Xiao J et al. The poor chemotherapeutic efficacy in lung adenocarcinoma overexpressing c-Src and nucleophosmin/B23(NPM1). Chinese Journal of Cellular and Molecular Immunology. 2016;32:1378–1381.
- Zhou LM, Yuan LL, Gao Y et al. Nucleophosmin 1 overexpression correlates with 18F-FDG PET/CT metabolic parameters and improves diagnostic accuracy in patients with lung adenocarcinoma. Eur J Nucl Med Mol Imaging. 2021 Mar;48(3):904-912. doi: 10.1007/s00259-020-05005-4. Epub 2020 Aug 27. PMID: 32856112.